Pharma company Biocon is set to announce its financial results for the quarter ended September 30, 2024, tomorrow, October 1 ...

Despite Biocon's assurances that the findings would not impact its business, investor sentiment appeared cautious.

Shares of Biocon have surged 44% in 2024 to date and 30% over the past two years, with the company currently holding a market ...

The inspection, which took place between September 23 and September 27, 2024, concluded with 4 observations from the ...

The scope of the inspection included one Drug Substance and one Drug Product manufacturing unit, a Medical Device Assembly ...

Biocon Ltd has entered a licensing and supply agreement with Tabuk Pharmaceutical Manufacturing Company to market GLP-1 ...

Biocon said that it has signed a licensing and supply agreement with Tabuk Pharmaceutical Manufacturing Company to commercialize its GLP-1 products for treating diabetes and chronic weight management, ...

Biocon has entered a partnership with Tabuk Pharmaceuticals for the commercialisation of glucagon-like peptide-1 (GLP-1) products in the Middle East. The collaboration aims to provide products for ...

The US Food and Drug Administration (USFDA) conducted a surveillance inspection of the API facility (Site 2), located at ...

Biocon's Bengaluru-based API facility received four observations from the USFDA following an inspection. The company plans to ...